Teacher Retirement System of Texas Purchases 11,082 Shares of Novavax, Inc. (NASDAQ:NVAX)

Teacher Retirement System of Texas boosted its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 35.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 42,773 shares of the biopharmaceutical company’s stock after purchasing an additional 11,082 shares during the quarter. Teacher Retirement System of Texas’ holdings in Novavax were worth $344,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. E Fund Management Co. Ltd. lifted its stake in shares of Novavax by 5.1% in the 4th quarter. E Fund Management Co. Ltd. now owns 25,340 shares of the biopharmaceutical company’s stock valued at $204,000 after purchasing an additional 1,219 shares during the period. Bank of New York Mellon Corp lifted its stake in Novavax by 0.4% in the fourth quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock valued at $3,509,000 after buying an additional 1,664 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in Novavax by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,965 shares of the biopharmaceutical company’s stock valued at $273,000 after buying an additional 3,174 shares during the period. Commonwealth Equity Services LLC boosted its holdings in Novavax by 8.1% during the fourth quarter. Commonwealth Equity Services LLC now owns 43,034 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 3,236 shares during the last quarter. Finally, Spire Wealth Management bought a new stake in shares of Novavax in the 4th quarter valued at about $29,000. 53.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on NVAX shares. TD Cowen raised shares of Novavax to a “hold” rating in a research note on Thursday, February 27th. BTIG Research assumed coverage on shares of Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $18.00.

Novavax Stock Performance

Shares of NVAX stock opened at $6.00 on Wednesday. The company has a market capitalization of $965.06 million, a P/E ratio of -2.65, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 52 week low of $3.81 and a 52 week high of $23.86. The company’s 50 day moving average price is $8.04 and its two-hundred day moving average price is $9.23.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million for the quarter, compared to analyst estimates of $85.48 million. During the same quarter in the previous year, the business earned ($1.44) earnings per share. Analysts forecast that Novavax, Inc. will post -1.46 earnings per share for the current year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.